{"disease":{"id":"recurrent-glioblastoma","name":"recurrent glioblastoma"},"drugs":{"marketed":[{"drug_id":"bevacizumab-maly","indication_name":"Recurrent Glioblastoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07448480","title":"Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Blokhin's Russian Cancer Research Center","has_results":false},{"nct_id":"NCT04427384","title":"Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"GT Medical Technologies, Inc.","has_results":false},{"nct_id":"NCT05902169","title":"Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":560,"lead_sponsor_name":"CarThera","has_results":false},{"nct_id":"NCT02017717","title":"A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":529,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT06283927","title":"The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)","phase":"","overall_status":"RECRUITING","enrollment_count":464,"lead_sponsor_name":"Jasper Gerritsen","has_results":false},{"nct_id":"NCT06273176","title":"The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma","phase":"","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT06325683","title":"Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":184,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03423628","title":"A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07349693","title":"Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":175,"lead_sponsor_name":"Everfront Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT03115333","title":"DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":146,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT04044937","title":"Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"Thomas Hope","has_results":false},{"nct_id":"NCT01609790","title":"Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06160206","title":"Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":false},{"nct_id":"NCT02974738","title":"A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT05432804","title":"Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment","phase":"PHASE1, PHASE2","overall_status":"SUSPENDED","enrollment_count":97,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05284643","title":"Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT01266031","title":"Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01814813","title":"Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":90,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":true},{"nct_id":"NCT07410494","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT06069726","title":"A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT05463848","title":"Surgical Pembro +/- Olaparib w TMZ for rGBM","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"L. Nicolas Gonzalez Castro, MD, PhD","has_results":false},{"nct_id":"NCT03632135","title":"Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Cordgenics, LLC","has_results":true},{"nct_id":"NCT03749187","title":"BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":78,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT04541225","title":"Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":74,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT01849146","title":"Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04223999","title":"Improving Tumor Treating Fields Treatment for Brain Cancer Patients With Skullremodeling Surgery (Neurosurgery)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"Anders Rosendal Korshøj","has_results":false},{"nct_id":"NCT02974621","title":"Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":70,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03434262","title":"SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT04477200","title":"Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":68,"lead_sponsor_name":"University of Michigan Rogel Cancer Center","has_results":false},{"nct_id":"NCT03914742","title":"BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":true},{"nct_id":"NCT02208362","title":"Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":65,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT02661282","title":"Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03782415","title":"Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"MediciNova","has_results":false},{"nct_id":"NCT03463265","title":"Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Aadi Bioscience, Inc.","has_results":true},{"nct_id":"NCT04003649","title":"IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05131711","title":"Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG)","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT05236036","title":"Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT04729959","title":"Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":59,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02323880","title":"Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT04388475","title":"Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Oblato, Inc.","has_results":false},{"nct_id":"NCT04528680","title":"Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT05465954","title":"Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03291314","title":"Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Universitair Ziekenhuis Brussel","has_results":false},{"nct_id":"NCT06616727","title":"The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":50,"lead_sponsor_name":"Shanghai Simnova Biotechnology Co.,Ltd.","has_results":false},{"nct_id":"NCT06090903","title":"Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04004975","title":"Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Shandong Cancer Hospital and Institute","has_results":false},{"nct_id":"NCT05557292","title":"RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Nicholas Butowski","has_results":false},{"nct_id":"NCT06455605","title":"D2C7-IT + 2141-V11 Combination Post-resection in rGBM","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Darell Bigner","has_results":false},{"nct_id":"NCT05739942","title":"Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":42,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04013672","title":"Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"David Peereboom","has_results":true}],"total":50},"guidelines":[{"drug_id":"zirabev","guideline_body":"FDA label","recommendation":"ZIRABEV is indicated for the treatment of recurrent glioblastoma (GBM) in adults.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"bevacizumab","guideline_body":"FDA label","recommendation":"MVASI is indicated for the treatment of recurrent glioblastoma (GBM) in adults.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}